KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Accumulated Expenses (2016 - 2025)

Vertex Pharmaceuticals has reported Accumulated Expenses over the past 17 years, most recently at $3.0 billion for Q4 2025.

  • Quarterly results put Accumulated Expenses at $3.0 billion for Q4 2025, up 6.55% from a year ago — trailing twelve months through Dec 2025 was $3.0 billion (up 6.55% YoY), and the annual figure for FY2025 was $3.0 billion, up 6.55%.
  • Accumulated Expenses for Q4 2025 was $3.0 billion at Vertex Pharmaceuticals, down from $3.6 billion in the prior quarter.
  • Over the last five years, Accumulated Expenses for VRTX hit a ceiling of $3.6 billion in Q3 2025 and a floor of $1.5 billion in Q2 2021.
  • Median Accumulated Expenses over the past 5 years was $2.6 billion (2023), compared with a mean of $2.5 billion.
  • Biggest five-year swings in Accumulated Expenses: fell 6.97% in 2021 and later surged 42.96% in 2022.
  • Vertex Pharmaceuticals' Accumulated Expenses stood at $1.7 billion in 2021, then rose by 26.69% to $2.1 billion in 2022, then rose by 24.86% to $2.7 billion in 2023, then increased by 5.02% to $2.8 billion in 2024, then rose by 6.55% to $3.0 billion in 2025.
  • The last three reported values for Accumulated Expenses were $3.0 billion (Q4 2025), $3.6 billion (Q3 2025), and $3.3 billion (Q2 2025) per Business Quant data.